What are the most commonly reported adverse reactions to indacaterol maleate (Onbrez Breezhaler) in patients with COPD?

At recommended doses of indacaterol maleate (Onbrez Breezhaler) in COPD, the most common adverse reactions were nasopharyngitis (14.3%), upper respiratory tract infection (14.2%), cough (8.2%), headache (3.7%) and muscle spasms (3.5%), mostly mild or moderate and becoming less frequent with continued treatment.